News for Chugai Pharmaceutical Co., Ltd. (4519.T)

TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates

**media[606500]**

Apr 24, 2025 / 09:00AM GMTPresentationApr 24, 2025 / 09:00AM GMT =====================Corporate Participants===================== * Kae Miyata Chugai Ph

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. ( TARA), a clinical-stage company developing transformative therapies for the treatmen

PR NewswireINDIANAPOLIS, April 17, 2025 Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average

Exploring the Strategic Moves of T. Rowe Price Japan Fund (Trades, Portfolio) in Q1 2025 T. Rowe Price Japan Fund (Trades, Portfolio) recently submitted its N-

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.( TARA), a clinical-stage company developing transformative therapies for the treatment

**media[592008]**

**media[558065]**

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable patients expecte

New data on Nemluvio® (nemolizumab), including an oral e-poster presentation characterizing the impact of Nemluvio in different pruriginous lesion types in prurigo …

https://mms.businesswire.com/media/20250213843444/en/2382130/19/GALDERMA_BERLIN_2025_INTERVIEW_YOUTUBE_V4.mp4 Ad hoc announcement pursuant to Art. 53 LR

Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q4 2024 Earnings Conference Call January 30, 2025 3:30 AM ETCompany ParticipantsKae Miyata - Head of Corporate...

The following slide deck was published by Chugai Pharmaceutical Co., Ltd.

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O N4519.T - Chugai Pharmaceutical Co LtdFull Year 2024 Chugai Pharmaceutical Co Ltd Earnings Pres

Japan stocks lower at close of trade; Nikkei 225 down 0.87%

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

Ad hoc announcement pursuant to Art. 53 LR